An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine

Sarah Moberley, Ross Andrews

Research output: Contribution to journalArticleResearchpeer-review

Abstract

We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumption
for non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.
Original languageEnglish
Pages (from-to)4-6
Number of pages3
JournalJournal of Vaccines & Immunization
Volume2
Issue number1
DOIs
Publication statusPublished - 2014

Fingerprint

Pneumococcal Vaccines
Clinical Trials
Control Groups

Cite this

@article{80c8d03316d14aaab6683340dd3ea1a4,
title = "An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine",
abstract = "We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumptionfor non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.",
author = "Sarah Moberley and Ross Andrews",
year = "2014",
doi = "10.14312/2053-1273.2014-1",
language = "English",
volume = "2",
pages = "4--6",
journal = "Journal of Vaccines & Immunization",
issn = "2053-1273",
publisher = "NobleResearch Publishers",
number = "1",

}

An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine. / Moberley, Sarah; Andrews, Ross.

In: Journal of Vaccines & Immunization, Vol. 2, No. 1, 2014, p. 4-6.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - An evaluation of the indirect cohort method to estimate the effectiveness of the pneumococcal polysaccharide vaccine

AU - Moberley, Sarah

AU - Andrews, Ross

PY - 2014

Y1 - 2014

N2 - We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumptionfor non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.

AB - We examined the validity of the indirect cohort method as a rapid assessment tool to estimate pneumococcal polysaccharide vaccine effectiveness (VE). Using evidence from published clinical trials, we reviewed the primary assumption about the appropriateness of the control group underpinning the indirect cohort method, which is that the risk of non-vaccine type invasive pneumococcal disease is equal for vaccinated and unvaccinated participants. We found an absence of evidence to support the non-differential risk assumptionfor non-vaccine type invasive pneumococcal disease occurring among clinical trial participants. In those instances where the design has been utilised, we also note that these typically rely on very small numbers of non-vaccine type invasive pneumococcal disease adding to the concerns as an unreliable comparator. We do not consider the indirect cohort method to be a valid tool for rapid assessment of pneumococcal polysaccharide VE.

U2 - 10.14312/2053-1273.2014-1

DO - 10.14312/2053-1273.2014-1

M3 - Article

VL - 2

SP - 4

EP - 6

JO - Journal of Vaccines & Immunization

JF - Journal of Vaccines & Immunization

SN - 2053-1273

IS - 1

ER -